Geron stock gains after Q2 revenue beat (GERN:NASDAQ)
· seekingalpha.com
Geron (GERN) stock jumps as the company's Q2 2026 revenue beats estimates thanks to growing demand for its blood cancer therapy, Rytelo. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...